Eli Lilly And Co (1LLY) Stock Price & News

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia

About Eli Lilly And Co

CEODavid A. Ricks

Employees50 миң

Founded1876

HeadquartersИндианаполис, Индиана, Америка Кошмо Штаттары

SectorPharmaceutical industry

Websitelilly.com

All values in USD	2025-ж. сен.	2025-ж. дек.	2026-ж. мар.	2026-ж. июн.
Revenue	17,60 млд	19,29 млд	19,80 млд	22,97 млд
Cost of goods sold	3,01 млд	3,37 млд	3,58 млд	3,27 млд
Cost of revenue	3,01 млд	3,37 млд	3,58 млд	3,27 млд
Research and development expenses	3,47 млд	3,80 млд	3,51 млд	3,82 млд
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2,63 млд	3,46 млд	2,93 млд	3,43 млд
Operating expense	6,09 млд	7,26 млд	6,44 млд	7,25 млд
Total operating expenses	9,10 млд	10,63 млд	10,02 млд	10,52 млд
Operating income	8,50 млд	8,66 млд	9,78 млд	12,46 млд
Other non operating income	-9,10 млн	181,20 млн	170,00 млн	561,00 млн
EBT including unusual items	7,23 млд	8,27 млд	8,85 млд	9,25 млд
EBT excluding unusual items	8,21 млд	8,89 млд	9,71 млд	12,73 млд
Income tax expense	1,65 млд	1,63 млд	1,45 млд	2,15 млд
Effective tax rate	22,81%	19,70%	16,43%	23,27%
Other operating expenses	-	-	-	-
Net income	5,58 млд	6,64 млд	7,40 млд	7,10 млд
Net profit margin	31,72%	34,41%	37,36%	30,88%
Earnings per share	7,02	7,54	8,55	8,38
Interest and investment income	65,00 млн	672,40 млн	-	-
Interest expense	-179,60 млн	-153,30 млн	-332,00 млн	-345,00 млн
Net interest expenses	-114,60 млн	519,10 млн	-332,00 млн	-345,00 млн
Depreciation and amortization charges	-	-	-	-
EBITDA	8,97 млд	9,25 млд	10,29 млд	12,99 млд
Gain or loss from assets sale	-	-180,00 млн	-	-

Ask anything